Christophe Weber: The Man Reshaping Takeda
Executive Summary
Christophe Weber became president and CEO of Japan's Takeda Pharmaceutical on April 1, 2015, in the process becoming both the first non-Japanese and first corporate outsider to hold the position at the more than 230-year old company. He has since initiated a ground-up refocusing and restructuring that will alter the fundamental shape of the company while retaining its core identity.
You may also be interested in...
Takeda Feels Need For Speed In Approaching Shire Integration
Takeda has fleshed out several aspects of its planned acquisition of Shire, emphasizing the need for speed and decisiveness if the integration is to be successful, although investors may need more reassurance ahead of required shareholder approval.
Takeda Closing In Again On Valeant Assets?
Takeda and Valeant are rumored to have restarted talks over some form of potential deal, this time reportedly focusing on a possible offer by the Japanese firm for Valeant's gastrointestinal business unit Salix.
Entyvio Takes Lead As Takeda Pursues Turnaround
Takeda’s CEO says the company is continuing to deliver on its turnaround plan after a stronger first half, with Entyvio providing much of the momentum for the underlying growth and a brighter full-term outlook.